HomeAmgen announces positive phase 3 results for dazodalibep in Sjögren's disease

Amgen announces positive phase 3 results for dazodalibep in Sjögren’s disease

Amgen has announced results from a phase 3 study of dazodalibep, the only global phase 3 trial to demonstrate clinically meaningful improvements in systemic disease activity and symptoms in patients with Sjögren’s disease.

The findings build on positive topline results announced in September and represent an important advance for a disease with no US Food and Drug Administration-approved treatments.

In the randomised, double-blind, placebo-controlled study, patients had a mean baseline score of 10.2 on the European Alliance of Associations for Rheumatology Sjögren’s Syndrome Disease Activity Index (ESSDAI), which measures systemic disease activity.

Both dazodalibep dosing regimens (1,500 mg every four weeks and 3,000 mg every 12 weeks) met the primary endpoint at week 48, demonstrating statistically significant reductions in systemic disease activity compared with placebo, as measured by the ESSDAI score.

The 1,500 mg every four weeks regimen (n=217) showed a least-squares mean reduction of 5.6 points from baseline in ESSDAI score, compared with 3.8 points for placebo (difference of 1.8 points; adjusted p<0.001).

The 3,000 mg every 12 weeks regimen (n=217) showed a reduction of 5.2 points, compared with 3.8 points for placebo (difference of 1.4 points; adjusted p=0.010). A treatment effect with dazodalibep was observed as early as week 4 and sustained through week 48.

At week 48, dazodalibep 1,500 mg every four weeks also significantly improved patient-reported dryness, a debilitating symptom of Sjögren’s disease, compared with placebo.

The placebo-adjusted least-squares mean differences in change from baseline were -1.17 points on the dryness domain of the EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) and -0.93 points on the dryness domain of the Diary for Assessing Sjögren’s Patient Reported Index (DASPRI) (adjusted p<0.001 for both).

- Advertisment -
- Advertisment -

Most Popular

Popular categories